A recent study found that rituximab maintenance therapy provides no additional benefit for patients with diffuse large B‐cell lymphoma (DLBCL) who are in complete remission after receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy.
A recent study found that rituximab maintenance therapy provides no additional benefit for patients with diffuse large B‐cell lymphoma (DLBCL) who are in complete remission (CR) after receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy.
The randomized phase 3 trial from the Netherlands assessed whether intensification of rituximab during the first 4 cycles of CHOP can improve outcomes, compared with standard R‐CHOP. It was previously shown that intensification of rituximab was not more effective than standard CHOP, showing same CR‐rates and progression free survival (PFS) after induction.
This study looked at the second randomization for rituximab maintenance therapy. Patients in CR after induction treatment were randomized between rituximab maintenance and observation. According to the trial registry, the patient population included previously untreated patients aged 66 to 80 years with stage 2 to stage 4 DLBCL and CD20-positive B cells.
Researchers randomized patients between 24 months of rituximab maintenance at a dose of 375 mg/m2 intravenously every 8 weeks (n = 199 ) or observation (n = 199). Computerized tomography scans were performed at 6, 12, 18 and 24 months in both arms.
The primary endpoint was disease-free survival (DFS) from maintenance randomization; secondary endpoints were overall survival (OS) and adverse events (AEs).
The majority of patients (54%) had a high‐intermediate or high age-adjusted International Prognostic Index (aaIPI) score. Nearly half were male with a median age of 65 years (range 31‐80); 48% were 66 years or older.
After a median follow‐up of 79.9 months (maximum 125.7 months), the 5‐year DFS rate was 79% for rituximab maintenance versus 74% for observation.
This difference was not statistically significant, with a hazard ratio of 0.83 (95% confidence interval 0.57‐1.19, P = .31, adjusted for age and aa‐IPI).
The secondary endpoint of OS was also not significantly different (85% versus 83% at 5 years).
In addition, no clinical subgroup benefited from rituximab maintenance.
Toxicity was mild; grade 3 and 4 AEs were reported in 17% and 6% of patients, respectively. Infection was the most frequent AE; neutropenia was seen in 1% (grade 3) and 3% (grade 4) of patients.
Reference
Lugtenburg P, de Nully Brown P, van der Holt B, et al. Rituximab maintenance for patients with diffuse large B‐cell lymphoma in first complete remission: results from a randomized Hovon‐Nordic lymphoma group phase III study. Presented at: 15th International Conference on Malignant Lymphoma Palazzo dei Congressi, June 18-22, 2019; Lugano, Switzerland. Abstract 043.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Similar Survival, Safety for Bevacizumab Biosimilar vs Originator in Colorectal Cancer
February 8th 2025A retrospective observational study found no significant differences in progression-free survival or safety in patients with colorectal cancers in Japan treated with ABP 215, Amgen’s bevacizumab biosimilar, or reference bevacizumab (Avastin), and estimated cost savings of 800,000 Japanese yen (approximately $5100) per patient with the biosimilar.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
A Banner Year for Biosimilars: The 19 FDA Approvals From 2024
January 21st 2025In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab and denosumab, marking significant progress in expanding treatment options and market competition.